Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute for Cancer Research

Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud

Hadassah Medical Organization Kiryat Hadassah

Vascular Biogenics Ltd.

Zvi Fuks

Michel Sadelain

Dror Harats

Richard N Kolesnick

Adriana Haimovitz-Friedman

Evis Sala

Alan A Alfieri

Jae H Kim

Sang H Kim

Israel Vlodavsky

Carlo Greco

Branka Stancevic

Nira Varda-bloom

Nira Varda-Bloom

The present disclosure provides methods and systems for treating tumors with radiotherapy, wherein a first dose of radiation is administered to a first sub-volume of the tumor and a second dose of radiation is administered to a second sub-volume of the tumor.

Perfusion modulated tumor dose sculpting with single dose radiotherapy

Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.

Enhancement of tumor response to chemotherapy by activation of the asmase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent

Enhancement of tumor response to chemotherapy by activation of the ASMase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent

Heparanase derived from human Sk-Hep-1 cell line

This invention provides a method of killing sarcoma cells in a patient by administering to the patient an effective amount of fludarabine phosphate effective to inhibit the repair of potentially lethal damage to the sarcoma cells and exposing the patient to an effective amount of ionizing radiation, effective to kill the sarcoma tumor cells in the patient.

Method of killing sarcoma cells using fludarabine phosphate and ionizing

Growing community of inventors

New York, NY, United States of America

Zvi Fuks